EW Healthcare Partners Mergers and Acquisitions Summary

Private Equity Profile

In the last 3 years, EW Healthcare Partners has acquired 1 company. It has also invested in 1 other.

EW Healthcare Partners’ most common sectors for investment are medical products (40%) and life science (30%). The Firm’s most common investment types include venture (60%) and growth capital (17%). In total, EW Healthcare Partners has invested in 17 US states and 6 different countries. Its largest (disclosed) acquisition occurred in 2004 when it acquired LipoSonix for $27M.

In the last 3 years, EW Healthcare Partners has exited 3 companies. The Firm’s most common exit type is trade sale (65%). EW Healthcare Partners’ largest (disclosed) exit occurred in 2012 when it sold EUSA Pharma for $680M.

Join Mergr to view EW Healthcare Partners’ full profile and discover more large private equity firms just like it.

M&A Summary

  • M&A Total Activity97
    • M&A Buy Activity55
    • M&A Sell Activity42
  • Total Sectors Invested 7
  • Total Countries Invested 6
  • M&A Buy/Sell Connections 50
  • M&A Advisors 4

EW Healthcare Partners

335 Bryant Street, 3rd Floor,
Palo Alto, California 94301
United States
(650) 543-1555
www.ewhealthcare.com
paloalto@ewhv.com

Essex Woodlands Health Ventures is a growth equity and venture capital specialist investment firm focused on opportunities across the healthcare sector. Specific areas of interest include biotechnology, pharmaceuticals, medical devices, and healthcare services/IT. Historically, Essex invested primarily in early and later-stage situations; however, today the firm also makes growth capital investments between $20 - $60 million in companies valued between $50 - $250 million, as well as private investments in public entities (PIPEs). Essex Woodlands was formed in 1985 and offices in Palo Alto, California; New York City; Houston, Texas; Shanghai and London.


Investment Criteria

Sectors of Interest: Healthcare Services, Information Technology, Life Science, Medical Products

Target Transaction Types: Buyout (LBO, MBO, MBI), Growth Capital, Venture

Geographic Preferences: East US, Midwest US, South US, West US, United Kingdom

Transaction Criteria Min Max
Target Revenue 20 200
Target EBITDA - -
Investment Size 20 80
Enterprise Value - -
values in millions of USD

M&A Summary

Buy vs Sell

Year ≤ '15 '16 '17 '18 '19 '20 T
Buy (1.0/yr) # 50 2 2 1 - - 55
vol $27M $15M $42M
Sell (0.8/yr) # 38 - 3 - 1 - 42
vol $4.8B $662M $5.4B
  97

Most Recent M&A

Company Date Value Type
Influence Health, Inc. 2019-01-08 - Add-on Acquisition
Birmingham, Alabama · www.influencehealth.com
Cognate BioServices, Inc. 2018-02-20 - Buyout (LBO, MBO, MBI)
Hanover, Maryland · www.cognatebioservices.com
Entellus Medical, Inc. 2017-12-07 662M USD Add-on Acquisition
Plymouth, Minnesota · www.entellusmedical.com
Grupo Farmaceutico Biotoscana S.A. 2017-08-22 - IPO
Montevideo, Uruguay · www.grupobiotoscana.com
Venus Concept Ltd. 2017-07-13 - Growth Capital
Toronto, Ontario · www.venusconcept.com
MedAvante, Inc. 2017-05-09 - Add-on Acquisition
Hamilton, New Jersey · ww.medavante.com
Xenex Disinfection Services LLC 2017-02-24 - Venture
San Antonio, Texas · www.xenex.com
Cota, Inc. 2016-12-20 - Growth Capital
New York, New Jersey · www.cotahealthcare.com
Metabolon, Inc. 2016-08-11 15M USD Growth Capital
Durham, North Carolina · www.metabolon.com
Open Monoclonal Technology, Inc. (OMT) 2015-12-17 178M USD Add-on Acquisition
Palo Alto, California · www.openmonoclonaltechnology.com
View All >>

Portfolio M&A

Company Acquired Add-On/Sale Date #
Cognate BioServices, Inc. 2018-02-20 Cobra Biologics 2019-11-04 1
Hanover, Maryland · www.cognatebioservices.com Keele Science Park, United Kingdom · www.cobrabio.com
Bioventus LLC 2012-05-07 BioStructures LLC 2015-11-30 2
Durham, North Carolina · www.bioventusglobal.com Durham, North Carolina · www.bioventusglobal.com
Bioventus LLC 2012-05-07 Advanced Biologics, LLC - OsteoAMP Product Line 2014-10-13 1
Durham, North Carolina · www.bioventusglobal.com , United States

M&A by Sector

Sector Current # Value All-time # Value
Medical Products 11 (41%) - 22 (40%) 27M (64%)
Life Science 7 (26%) 15M (100%) 16 (29%) 15M (36%)
Healthcare Services 5 (19%) - 10 (18%) -
Information Technology 2 (7%) - 3 (5%) -
Internet Software and Services 1 (4%) - 2 (4%) -
Software - - 1 (2%) -
Technology Hardware 1 (4%) - 1 (2%) -
Total 27 $15M 55 $42M

Acquisitions By Geo

State/Country Current # Value All-time # Value
United States 23 (85%) 15M (100%) 49 (89%) 42M (100%)
  California 8 (30%) - 20 (36%) 27M (64%)
  Pennsylvania - - 5 (9%) -
  North Carolina 3 (11%) 15M (100%) 3 (5%) 15M (36%)
  Washington 2 (7%) - 2 (4%) -
  New York 2 (7%) - 2 (4%) -
  Maryland 1 (4%) - 2 (4%) -
  Texas 1 (4%) - 2 (4%) -
  New Jersey 1 (4%) - 2 (4%) -
  Massachusetts 1 (4%) - 2 (4%) -
  Illinois - - 2 (4%) -
  Kentucky 1 (4%) - 1 (2%) -
  Florida 1 (4%) - 1 (2%) -
  Utah 1 (4%) - 1 (2%) -
  Tennessee 1 (4%) - 1 (2%) -
  Georgia - - 1 (2%) -
  Alabama - - 1 (2%) -
  Minnesota - - 1 (2%) -
United Kingdom 1 (4%) - 2 (4%) -
Canada 1 (4%) - 1 (2%) -
  Ontario 1 (4%) - 1 (2%) -
Denmark 1 (4%) - 1 (2%) -
Switzerland 1 (4%) - 1 (2%) -
Uruguay - - 1 (2%) -
Domestic 23 (85%) 15M (100%) 49 (89%) 42M (100%)
Cross-border 4 (15%) - 6 (11%) -
Total 27 $15M 55 $42M

Acquisitions by Deal Type

Type Current # Value All-time # Value
Venture 17 (63%) - 33 (60%) 27M (64%)
Growth Capital 3 (11%) 15M (100%) 9 (16%) 15M (36%)
Buyout (LBO, MBO, MBI) 2 (7%) - 6 (11%) -
Stake Purchase 2 (7%) - 3 (5%) -
PIPE 2 (7%) - 2 (4%) -
Recapitalization 1 (4%) - 1 (2%) -
Secondary Buyout - - 1 (2%) -
Total 27 $15M 55 $42M

Exits by Deal Type

Type Total # Value
Trade Sale - Public Company 20 (48%) 4.6B (84%)
IPO 9 (21%) -
Trade Sale 8 (19%) 880M (16%)
Merger 3 (7%) -
Secondary Sale 2 (5%) -
Total 42 $5.4B

Top M&A Advisors

Financial Deals
PwC Corporate Finance LLC
 1
Legal Deals
Kirkland & Ellis LLP
 1
Reed Smith LLP
 1
Perkins Coie LLP
 1

Deal Values

buy # Total
< $100M 2 $42M
TOTAL $42M
Largest LipoSonix, Inc.
$27M (2004-07-11)
sell # Total
$100M to $1B 17 $5.2B
< $100M 4 $260M
TOTAL $5.4B
Largest EUSA Pharma, Inc.
$680M (2012-04-30)

M&A Connections

Deals %
Acquired from
PE Firm(s)
100%
3 100%
Exited to
PE Firm(s)
6%
2 6%
Strategic(s)
94%
31 94%

Investor Summary

Size

Large

PE Assets

2.5B USD

Established

1985

Specialist/Generalist

Specialist

Leadership

Marty Sutter

Co-Founder & Managing Director

Scott Barry

Managing Director

Ron Eastman

Managing Director

Petri Vainio

Managing Director

Guido J. Neels

Operating Partner

 Subscribe to unlock this and 151,843
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More
1 Week Free Trial Learn More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB

Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 3.9K Private Equity Firms
  • 139K M&A Transactions
  • 148K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.1K M&A Advisors
    (Investment Banks and Law Firms)
  • 41K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.

Mergr

Product

Company

Legal